SynthesisBMJ open gastroenterology2024
Systematic review and meta-analysis of biomarkers predicting decompensation in patients with compensated cirrhosis.
Synthesis in BMJ open gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic biomarkers for predicting decompensation in alcoholic and non-alcoholic patients with compensated cirrhosis: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Bacterial Infections in Patients With Severe Alcohol-Associated Hepatitis: Drivers of Organ Failure and Mortality.Liver international : official journal of the International Association for the Study of the Liver · 2025Trial
- A multicenter multistate modeling on the natural history of liver decompensation: Longitudinal analysis of 1777 patients.Hepatology communications · 2026Article
- Child-Pugh Stage Predicts Survival in Hospitalized Patients with Decompensated Cirrhosis: A 10-Year Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Metabolic syndrome is independently associated with 1-year readmission in patients with alcohol-associated cirrhosis.Frontiers in medicine · 2026Article
- Prognostic Biomarkers for Predicting Decompensation in Alcoholic and Nonalcoholic Patients With Compensated Cirrhosis: An Umbrella Review.Biochemistry research international · 2026Review
- Observational
- Electroencephalography in hepatic encephalopathy: diagnostic and prognostic applications across the disease spectrum.Annals of gastroenterology · 2026Review
- Article
- Elevated serum ferritin as a predictor of complications in cirrhotic patients: a retrospective cohort study.BMC gastroenterology · 2025Observational
- Review
- Hepatic cirrhosis and decompensation: Key indicators for predicting mortality risk.World journal of hepatology · 2025Review
- Assessing the Predictive Value of NLR and PLRs in Advanced Hepatocellular Carcinoma Patients Receiving First-line Systemic Therapy: Observations from a Tertiary Care Hospital in Pakistan.Euroasian journal of hepato-gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe transition from compensated to decompensated cirrhosis is crucial, drastically reducing prognosis from a median survival of over 10 years to 2 years. There is currently an unmet need to accurately predict decompensation. We systematically reviewed and meta-analysed data regarding biomarker use to predict decompensation in individuals with compensated cirrhosis.
methodsPubMed and EMBASE database searches were conducted for all studies from inception until February 2024. The study was carried out according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The Quality of Prognosis Studies framework was used to assess the risk of bias. The meta-analysis was conducted with a random effects model using STATA software.
resultsOf the 652 studies initially identified, 63 studies (n=31 438 patients) were included in the final review, examining 49 biomarkers. 25 studies (40%) were prospective with the majority of studies looking at all-cause decompensation (90%). The most well-studied biomarkers were platelets (n=17), Model for End-Stage Liver Disease (n=17) and albumin (n=16). A meta-analysis revealed elevated international normalised ratio was the strongest predictor of decompensation, followed by decreased albumin. However, high statistical heterogeneity was noted (l
conclusionsThis review highlights key biomarkers that should potentially be incorporated into future scoring systems to predict decompensation. However, future biomarker studies should be conducted with rigorous and standardised methodology to ensure robust and comparable data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.